What were the primary drivers of Gilead's revenue growth in 2003?

Gilead's revenue growth in 2003 was primarily driven by strong sales of its HIV medication, Viread, which accounted for 65% of total revenues. Sales of its antifungal medication, AmBisome, also contributed significantly, making up 24% of total revenues.

What was the strategic rationale behind the acquisition of Triangle Pharmaceuticals?

The acquisition of Triangle Pharmaceuticals in January 2003 was a strategic move to expand Gilead's antiviral pipeline, particularly for HIV and Hepatitis B. The acquisition brought in key drug candidates like Emtriva (emtricitabine) and strengthened Gilead's position in the infectious disease market.

How did the Triangle acquisition impact Gilead's financial performance in 2003?

The acquisition of Triangle Pharmaceuticals involved a significant charge for in-process research and development ($488.6 million), which resulted in an operating loss of $158.7 million for Gilead in 2003. However, it also added valuable assets to Gilead's pipeline and contributed to a strong increase in operational cash flow.

GILD 10-K FY2003 Annual Report — Revenue, Net Income, EPS

Q: What is Gilead's outlook for its HIV franchise, specifically regarding Viread and Emtriva?

Gilead expects its HIV drug sales to continue growing, albeit at a slower rate than in the previous two years. The company is developing a fixed-dose combination of Viread and Emtriva into a single pill, designed for once-daily dosing, which is anticipated to further enhance its HIV franchise and patient convenience.

Summary

Gilead Sciences, Inc.'s 2003 Form 10-K highlights a year of significant growth driven primarily by its HIV franchise, particularly Viread. The company reported total revenues of $867.9 million, with Viread contributing $566.5 million (65%) and AmBisome accounting for $210.9 million (24%). The acquisition of Triangle Pharmaceuticals in January 2003 for $525.2 million, largely allocated to in-process R&D, aimed to bolster Gilead's antiviral pipeline, notably adding Emtriva (emtricitabine) for HIV treatment and advancing potential hepatitis B therapies. Despite a substantial in-process R&D charge impacting operating results negatively for the year ($158.7 million operating loss), Gilead demonstrated robust operational cash flow ($234.6 million). The company is strategically focused on infectious diseases and is actively developing a fixed-dose combination of Viread and Emtriva, which is expected to enhance its HIV franchise. While facing increasing competition in its key markets, Gilead's strong product portfolio, ongoing R&D efforts, and strategic acquisitions position it for continued growth in the biopharmaceutical sector.

Key Highlights

1Total revenues reached $867.9 million, a substantial increase driven by Viread and AmBisome.
2Viread was the leading revenue generator, accounting for 65% of total revenues ($566.5 million), underscoring its critical role in the HIV treatment market.
3The acquisition of Triangle Pharmaceuticals for $525.2 million significantly expanded Gilead's antiviral pipeline, adding Emtriva and other drug candidates.
4A large portion of the Triangle acquisition ($488.6 million) was attributed to in-process research and development, resulting in an operating loss for the year but strengthening future potential.
5Operational cash flow increased significantly to $234.6 million, demonstrating the company's ability to generate cash from its core business.
6Gilead is actively developing a fixed-dose combination of Viread and Emtriva, aiming for a convenient once-daily oral regimen for HIV patients.
7The company continues to invest heavily in R&D, with expenses totaling $164.9 million, focusing on infectious diseases, particularly antivirals and antifungals.

GILEAD SCIENCES, INC. Annual Report, Year Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions